Biliary System Disorder, Cholangiocarcinoma, Gall Bladder Carcinoma
Conditions
Keywords
Prognosis, Surgery options, Bayesian networks
Brief summary
Malignant tumors of biliary system lack standard treatment and precise prognosis assessment methods. This study including 12 hospitals, collecting clinical and follow-up data of patients with biliary malignant tumors including cholangiocarcinoma and gallbladder carcinoma in recent 10 years, aim to build a special disease database, then use Bayesian networks and importance theory to establish a mathematical model to assess treatment strategies and prognosis accurately. At the same time, data on biliary malignant tumors newly treated by multicenters from 2018 to 2020 will be included to validate, adjust and refine the models to guide clinical individualized precise treatment.
Interventions
None listed
Sponsors
First Affiliated Hospital Xi'an Jiaotong University
The First Affiliated Hospital of Zhengzhou University
The First Affiliated Hospital of Dalian Medical University
Shanghai Zhongshan Hospital
Southwest Hospital, China
Tianjin Medical University Cancer Institute and Hospital
Sun Yat-sen University
Affiliated Hospital of North Sichuan Medical College
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Second Affiliated Hospital, School of Medicine, Zhejiang University
Eastern Hepatobiliary Surgery Hospital
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
： * Clinical diagnosis of biliary malignancy including gallbladder carcinoma or cholangiocarcinoma verified by pathological results * Must be able to undergo surgery * Undergoing radical surgery for biliary malignancy (R0 or R1 resection) * Not complicated with other malignancy * No other treatments before and during surgery, such as radiotherapy and chemotherapy.
Exclusion criteria
* Non-primary gallbladder or cholangiocarcinoma * With distant metastasis (M1 phase) * Incomplete follow-up data * Died within 30 days after surgery.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Death from biliary tract carcinoma | Every three months, up to five years | Death from cholangiocarcinoma or gallbladder carcinoma |
Countries
China
Contacts
Primary ContactZhaohui Tang, MD,PhD
Backup ContactMiaoyan Wei, MD,PhD
Outcome results
None listed